TP53 H179Y

CI-VAR-00001908Explore in graph →NP_000537.3:p.His179TyrNM_000546.5:c.535C>TClinVar 127815 CIViC 1083 rs587780070

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease1unmapped disease
TP53 H179Y	(functional)	Functional	D	Supports Dominant Negative	3	accepted	EID10247 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
127815	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Li-Fraumeni syndrome; Li-Fraumeni syndrome 1; Ovarian neoplasm; Hereditary cancer-predisposing syndrome; Adrenocortical carcinoma, hereditary; Neoplasm; Diffuse midline glioma, H3 K27M-mutant; Primary intracranial sarcoma, DICER1-mutant	germline/somatic	12	Mar 18, 2025